ArticleAmerican journal of translational research2026
Efficacy evaluation and mechanism exploration of Dachaihu Decoction in treating hyperlipidemia: an integrated network meta-analysis and network pharmacology study.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDachaihu Decoction (DCHD), a traditional herbal formula from Shanghan Lun, has been widely used in the management of hyperlipidemia. However, the comparative efficacy of its modified formulations and their underlying mechanisms remain unclear. This study aimed to evaluate the therapeutic efficacy of DCHD and its modifications and to elucidate the potential mechanisms using integrated analytical strategies.
methodsWe conducted a Bayesian network meta-analysis (NMA) of randomized controlled trials (RCTs) systematically retrieved from multiple databases up to May 2024, following the PRISMA-NMA Guidelines. Lipid parameters, including total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C), as well as response rates, were evaluated. In addition, network pharmacology, molecular docking, and molecular dynamics (MD) simulations were performed to further explore the underlying mechanisms.
resultsA total of 23 randomized controlled trials (RCTs) involving 1,816 patients were included. The surface under the cumulative ranking curve (SUCRA) analysis indicated that Dachaihu Decoction combined with Shengjiang Powder had the highest efficacy in reducing TC, TG, and LDL-C in patients with hyperlipidemic pancreatitis. However, sensitivity analysis revealed that Dachaihu Decoction alone and in combination with Guizhi Fuling Pill showed more stable efficacy in chronic populations. Network pharmacology identified 69 active components, including quercetin, β-sitosterol, and baicalein, and 305 intersecting targets. Protein-protein interaction (PPI) analysis highlighted TLR4, MMP9, SIRT1, ICAM1, and GSK3B as core targets. KEGG pathway enrichment analysis indicated significant involvement in lipid metabolism and inflammatory pathways. Molecular docking and molecular dynamics simulations revealed that the β-sitosterol-ICAM1 complex exhibited stable conformational stability, with an MM-GBSA binding free energy of -37.09 kcal/mol.
conclusionsModified DCHD formulations showed therapeutic potential for hyperlipidemia through multi-target and multi-pathway synergistic mechanisms. DCHD combined with Shengjiang Powder appears particularly promising in hyperlipidemic pancreatitis, whereas DCHD alone shows stable efficacy in chronic populations. These findings provide robust evidence supporting the rational clinical application and modern pharmacological interpretation of the classical formula DCHD documented in Shanghan Lun.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.